Tai Chi Group's Southwest Pharma Receives Approval for Digoxin Injection Generic Equivalence on May 22

GateNews
Tai Chi Group announced on May 22 that its subsidiary Southwest Pharma received approval from China's National Medical Products Administration for digoxin injection (2ml: 0.5mg) to pass generic drug quality and efficacy consistency evaluation.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments